Antimicrobial Essential Oil Formulation: Chitosan Coated Nanoemulsions for Nose to Brain Delivery.
Syzygium aromaticum
Thymus vulgaris
antibacterial activity
chitosan coating
essential oils
nanoemulsions
nose to brain delivery
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
17 Jul 2020
17 Jul 2020
Historique:
received:
14
05
2020
revised:
14
07
2020
accepted:
14
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Brain infections as meningitis and encephalitis are attracting a great interest. Challenges in the treatment of these diseases are mainly represented by the blood brain barrier (BBB) that impairs the efficient delivery of even very potent drugs to reach the brain. The nose to the brain administration route, is a non-invasive alternative for a quick onset of action, and enables the transport of numerous medicinal agents straight to the brain thus workarounding the BBB through the highly vascularized olfactory region. In this report,
Identifiants
pubmed: 32709076
pii: pharmaceutics12070678
doi: 10.3390/pharmaceutics12070678
pmc: PMC7407154
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Sapienza Università di Roma
ID : Ateneo 2019 (prot. RM11916B8876093E) (Ateneo 2018 prot. RM118164361B425B)
Références
Artif Cells Nanomed Biotechnol. 2018 Jun;46(4):717-729
pubmed: 28604104
Antimicrob Resist Infect Control. 2018 Jan 19;7:8
pubmed: 29387342
Colloids Surf B Biointerfaces. 2019 Nov 1;183:110446
pubmed: 31465938
J Control Release. 2018 Jan 28;270:89-100
pubmed: 29199063
Int J Pharm. 2014 Jan 2;460(1-2):131-43
pubmed: 24239580
Arq Neuropsiquiatr. 2014 May;72(5):398-9
pubmed: 24863522
Nanoscale. 2017 Jan 19;9(3):1174-1183
pubmed: 28009915
Curr Pharm Des. 2015;21(36):5225-32
pubmed: 26412357
Colloids Surf B Biointerfaces. 2014 Mar 1;115:286-94
pubmed: 24388859
J Neurol. 2008 Nov;255(11):1617-24
pubmed: 19156484
Open Microbiol J. 2014 Feb 07;8:6-14
pubmed: 24627729
J Pharm Sci. 2020 Jul;109(7):2237-2251
pubmed: 32320670
Int J Pharm. 2019 Jun 30;565:258-268
pubmed: 31095983
Molecules. 2018 Oct 09;23(10):
pubmed: 30304862
Mol Pharm. 2014 Feb 3;11(2):531-44
pubmed: 24320221
Drug Deliv. 2018 Nov;25(1):376-387
pubmed: 29382237
Pharm World Sci. 2004 Jun;26(3):137-42
pubmed: 15230360
Pharmaceutics. 2018 Mar 26;10(2):
pubmed: 29587409
Evid Based Complement Alternat Med. 2014;2014:651593
pubmed: 24971152
Br J Neurosurg. 2019 Jul 25;:1-3
pubmed: 31342790
Pharmaceutics. 2019 Dec 19;12(1):
pubmed: 31861717
Lett Appl Microbiol. 2016 Nov;63(5):322-334
pubmed: 27542872
Curr Opin HIV AIDS. 2014 Nov;9(6):585-90
pubmed: 25226025
Clin Infect Dis. 2017 Mar 15;64(6):e34-e65
pubmed: 28203777
Colloids Surf B Biointerfaces. 2013 Mar 1;103:158-65
pubmed: 23201733
Eur J Pharm Biopharm. 2017 Jan;110:13-18
pubmed: 27989765
J Enzyme Inhib Med Chem. 2017 Dec;32(1):1265-1273
pubmed: 28965424
Nat Prod Res. 2020 Feb;34(3):445-448
pubmed: 30602287
J Neurosci Methods. 2004 Jan 15;132(1):35-43
pubmed: 14687673
Pharmaceutics. 2018 Mar 22;10(2):
pubmed: 29565809
Pharmaceutics. 2019 Feb 17;11(2):
pubmed: 30781585
Colloids Surf B Biointerfaces. 2019 Nov 1;183:110439
pubmed: 31473410
J Control Release. 2016 Aug 10;235:337-351
pubmed: 27297779
J Pharmacol Exp Ther. 2002 Apr;301(1):391-400
pubmed: 11907197
J Neuroimmune Pharmacol. 2017 Mar;12(1):17-30
pubmed: 27832401
Molecules. 2019 Mar 03;24(5):
pubmed: 30832446
Curr Pharm Des. 2017;23(17):2504-2531
pubmed: 27908273
Expert Rev Anti Infect Ther. 2014 Mar;12(3):333-42
pubmed: 24512210
Adv Drug Deliv Rev. 1998 Jan 5;29(1-2):13-38
pubmed: 10837578